EMA Authorised: Ryjunea (atropine sulfate) — Santen Oy

View source ↗

Summary

EMA authorised Ryjunea (atropine sulfate) for myopia, marketed by Santen Oy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myopia

Drugs mentioned

• Ryjunea (atropine sulfate)

Snippet

Status: Authorised. Therapeutic area: Myopia. MAH: Santen Oy. Decision date: 22/07/2026